India’s pharmaceutical industry is accelerating its transition towards high-value medicines, complex chemistry and advanced therapies. At the same time, domestic manufacturers are increasing investments in active pharmaceutical ingredient (API) production to reduce import dependence, strengthen supply chains and improve global competitiveness. Industry executives have emphasised the need to expand research and development (R&D), adopt advanced manufacturing technologies and develop proprietary chemical platforms to strengthen India’s pharmaceutical manufacturing capabilities. Industry leaders believe that innovation, sustainable manufacturing and technological advancements will play a crucial role in shaping the sector’s next phase of growth.
Jubilant Ingrevia Invests in Advanced Pharmaceutical Manufacturing
Deepak Jain, CEO and Managing Director of Jubilant Ingrevia, said India’s pharmaceutical industry was increasingly adopting innovation-led and sustainable manufacturing practices to address changing healthcare requirements and growing demand for resilient global supply chains. He highlighted that the company had invested approximately Rs 2,000 crore over the past three years to establish manufacturing facilities across 35 technology platforms. These facilities also leverage artificial intelligence (AI)-enabled manufacturing to improve operational efficiency. The company aims to source more than 35% of its energy requirements from renewable sources, reflecting its commitment to sustainable industrial operations.
Rising Demand for Medicines Drives Pharmaceutical Market Growth
Increasing demand for treatments targeting diabetes, metabolic disorders and cancer is creating new growth opportunities for India’s pharmaceutical industry. According to IQVIA data, India’s domestic pharmaceutical market recorded 17.1% year-on-year growth in September 2026, marking its strongest monthly expansion in three years. Additionally, government incentives, rising export demand and investments in domestic manufacturing are supporting the industry’s expansion. India’s pharmaceutical exports reached USD 30.47 billion in FY25. Meanwhile, exports during April-June 2026-27 stood at USD 8.10 billion, registering 6.8% year-on-year growth, according to Pharmexcil data.
Industry Calls for Reduced Dependence on Imported APIs
Reducing dependence on imported bulk drugs and active pharmaceutical ingredients remains another key priority for India’s pharmaceutical sector. Pankaj Banerjee, Head of Global Exports Business and Senior General Manager at Hamdard Laboratories India, stressed the importance of strengthening domestic API manufacturing capabilities. India imported approximately USD 4.35 billion worth of bulk drugs and APIs in FY25, with China accounting for 73.71% of the total imports. To address this dependence, Banerjee called for greater investment in compliant agricultural sourcing, standardised herbal extracts and Good Manufacturing Practice (GMP) systems. He noted that strengthening these areas would support domestic pharmaceutical and AYUSH manufacturing while improving product quality and supply-chain resilience.
Advanced Packaging Gains Importance in Pharmaceutical Manufacturing
Industry executives also highlighted the growing importance of advanced packaging technologies in ensuring pharmaceutical safety, dosage accuracy and patient compliance. Shiva Kabra, Joint Managing Director of Control Print Ltd, said packaging had become an integral part of pharmaceutical innovation and product protection. The company plans to showcase its single-dose packaging solutions and automated filling lines at PMEC India 2026, highlighting the role of automation and advanced packaging technologies in modern pharmaceutical manufacturing.
Automation and PLI Scheme Support Industry Growth
Yogesh Mudras, Managing Director of Informa Markets in India, said investments in automation, API manufacturing and quality management systems were accelerating technological advancements across the pharmaceutical sector. He also highlighted the contribution of the government’s Production Linked Incentive (PLI) scheme, which had generated approximately 1.15 lakh jobs by March 2026. The scheme aims to strengthen domestic manufacturing, encourage investment and improve India’s competitiveness in the global pharmaceutical supply chain.
India’s Pharmaceutical Industry Strengthens Focus on Innovation
India’s shift towards high-value medicines, domestic API manufacturing and advanced production technologies reflects its ambition to strengthen its position in the global pharmaceutical market. As reported by knnindia.co.in, investments in R&D, automation, sustainable manufacturing, advanced packaging and domestic supply chains will remain essential to improving competitiveness and reducing import dependence. These developments could also help India move beyond conventional drug manufacturing towards higher-value pharmaceutical products and advanced therapies.




